Edition:
United States

Soligenix Inc (SNGX.OQ)

SNGX.OQ on NASDAQ Stock Exchange Capital Market

1.65USD
18 May 2018
Change (% chg)

$-0.03 (-1.79%)
Prev Close
$1.68
Open
$1.65
Day's High
$1.65
Day's Low
$1.63
Volume
2,252
Avg. Vol
22,277
52-wk High
$3.70
52-wk Low
$1.58

Chart for

About

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical... (more)

Overall

Beta: 2.19
Market Cap(Mil.): $13.11
Shares Outstanding(Mil.): 5.72
Dividend: --
Yield (%): --

Financials

  SNGX.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -1.30 -- --
ROI: -330.88 1.57 14.38
ROE: -330.88 2.43 16.07

BRIEF-Soligenix Reports Q1 Loss Per Share Of $0.27

* SOLIGENIX ANNOUNCES RECENT ACCOMPLISHMENTS AND FIRST QUARTER 2018 FINANCIAL RESULTS

May 11 2018

BRIEF-Soligenix Receives Orphan Drug Designation From The European Commission For Rivax For Prevention Of Ricin Poisoning

* SOLIGENIX RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN COMMISSION FOR RIVAX® FOR PREVENTION OF RICIN POISONING Source text for Eikon: Further company coverage:

Mar 22 2018

BRIEF-Soligenix - Driving Towards Key Inflection Points With Two Pivotal Phase 3 Clinical Trials

* SOLIGENIX - DRIVING TOWARDS KEY INFLECTION POINTS WITH TWO PIVOTAL PHASE 3 CLINICAL TRIALS Source text for Eikon: Further company coverage:

Jan 25 2018

BRIEF-Soligenix Announces US Patent Issuance For Use Of Dusquetide In Oral Mucositis

* SOLIGENIX ANNOUNCES US PATENT ISSUANCE FOR USE OF DUSQUETIDE IN ORAL MUCOSITIS Source text for Eikon: Further company coverage:

Jan 02 2018

BRIEF-Soligenix Identifies Biomarkers For Ricin Toxin Vaccine Testing Under FDA Animal Rule

* SOLIGENIX IDENTIFIES BIOMARKERS FOR RICIN TOXIN VACCINE TESTING UNDER THE FDA ANIMAL RULE

Dec 21 2017

Earnings vs. Estimates